Table 1 Demographics and clinical baseline characteristics of the included patients (n = 31). Data are presented as the median [range] or number (%)
Total number of patients: N = 31 | |||
|---|---|---|---|
Age (years) | 69; Min–Max 46–80; Interquartile range, 62–72 | ||
Cancer types | |||
Endometrial carcinoma | 18 (58.1) | ||
Serous carcinoma | 11 (35.5) | ||
Carcinosarcoma | 2 (6.5) | ||
Number of previous lines of treatment | |||
0–1 | 2 (6.5) | ||
2–3 | 12 (38.7) | ||
4–5 | 8 (25.8) | ||
≥6 | 9 (29.0) | ||
Previous treatment with radiotherapy | |||
Yes | 3 (9.7) | ||
No | 28 (90.3) | ||
Previous treatment with immunotherapy | |||
Yes | 2 (6.5) | ||
No | 29 (93.5) | ||
Previous treatment with endocrine therapy | |||
Minimum one line of endocrine treatment | 5 (16.1) | ||
Acetate megestrol | 3 (9.6) | ||
Tamoxifen | 2 (6.5) | ||
Aromatase inhibitor | 3 (9.7) | ||
Molecular subtypes: n = 20 | |||
POLE | 0 (0% of 20 available) | ||
dMMR/MSI High | 3 (15% of 20 available) | ||
Non-specific molecular profile (NSMP) | 4 (20% of 20 available) | ||
TP53 altered | 13 (65% of 20 available) | ||
Large genomic alteration (LGA) score: n = 23 | |||
LGA ≤ 7 | 15 (65.2% of 23 available) | ||
LGA ≥ 8 | 8 (34.8% of 23 available) | ||
BRCA1/2 mutation | 1 (5.5% of 18 available) | ||
